HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in…
— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other…